美国心脏病学会重磅发布：这两款药物成减肥"黄金标准"！

Core Viewpoint - The American College of Cardiology (ACC) has officially recognized semaglutide and tirzepatide as preferred medications for obesity treatment, marking a significant shift in the management of obesity and its associated cardiovascular risks [7][10]. Summary by Sections Breakthrough Therapies - Innovative drugs like semaglutide and tirzepatide not only significantly reduce weight but also provide additional cardiovascular protection for high-risk patients, particularly those with type 2 diabetes or existing cardiovascular diseases [10]. Obesity as a Health Threat - Obesity is highlighted as a serious health risk, leading to metabolic disorders, respiratory issues, and various heart diseases. It is recognized as an independent risk factor for cardiovascular diseases [11]. Weight Loss Thresholds - Different weight loss percentages yield varying cardiovascular benefits: a 10%-15% weight loss can reduce general cardiovascular risks, while heart failure patients may need to lose over 15% for significant improvement [12]. Treatment Options - The treatment landscape includes lifestyle interventions, weight loss surgery, and pharmacotherapy. The ACC suggests a reevaluation of the traditional approach of prioritizing lifestyle changes before medication [15]. Third-Generation Weight Loss Drugs - Semaglutide and tirzepatide represent a revolutionary choice in obesity management, with long-term efficacy and safety data supporting their use for weight loss [16]. Weight Loss Effectiveness - Comparative data shows that semaglutide leads to an average weight loss of 14.9%, while tirzepatide achieves an average of 20.9%, making it the most effective option currently available [18][20]. Long-Term Treatment Importance - Long-term treatment is crucial as stopping medication can lead to weight regain. Continuous use combined with lifestyle adjustments is essential for maintaining weight loss [21]. Accessibility and Economic Burden - The main challenges for semaglutide and tirzepatide include limited supply and high costs, which may affect patient access to these therapies [22]. Cardiovascular Benefits Beyond Weight Loss - The NuSH therapy not only aids in weight loss but also reduces the risk of heart attacks and strokes in obese patients without diabetes, and improves outcomes for heart failure patients [23]. Approved Weight Loss Medications in China - The 2024 guidelines in China have approved five medications for adult weight loss, emphasizing a multidisciplinary approach to obesity treatment [24].